

10/523055  
 Rec'd PCT/PTO 27 SEP 2005

PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM</b>	<b>Application Number</b>	PCT/EP2003/008569	
	<b>Filing Date</b>	31 July 2003	
	<b>First Named Inventor</b>	Ralph BIEMANS	
	<b>Title</b>	VACCINE COMPOSITION COMPRISING LIPOOLIGOSACCHARIDE WITH REDUCED PHASE VARIABILITY	
	<b>Art Unit</b>		
	<b>Examiner Name</b>		
<b>Attorney Docket Number</b>		B45309	
I hereby appoint: <input checked="" type="checkbox"/> Practitioners associated with the Customer Numbers. 20462 Or <input type="checkbox"/> Practitioner(s) named below:			
Name		Registration Number	
As my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.			
Please recognize or change the correspondence address for the above-identified application to: <input type="checkbox"/> The address associated with the above-mentioned Customer Number: Or <input checked="" type="checkbox"/> The address associated with Customer Number 20462			
Or <input type="checkbox"/> Firm or Individual Name:			
Address:			
Address:			
City:		State:	Zip:
Country:			
Telephone:		Fax:	
I am the: <input type="checkbox"/> Applicant/Inventor: <input checked="" type="checkbox"/> Assignee or record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)			
SIGNATURE of Applicant or Assignee of Record			
Signature: <i>Marcus Jonathan William Dalton</i>		Date: 09 MAY 2005	
Name: Marcus Jonathan William DALTON		Telephone: +44 20 8047 4401	
Title and Company: Attorney and Authorised Official, GlaxoSmithKline Biologicals s.a.			
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.			
<input type="checkbox"/> *Total of: forms are submitted.			

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

**STATEMENT UNDER 37 CFR 3.73(b)**

Applicant/Patent Owner: GlaxoSmithKline Biologicals s.a.

International Application No./Patent No.: PCT/EP2003/008569 Filed/Issue Date: 31 July 2003Entitled: VACCINE COMPOSITION COMPRISING LIPOOLIGOSACCHARIDE WITH REDUCED PHASE VARIABILITY

GlaxoSmithKline Biologicals s.a., a corporation, states that it is:

1. ☐ the assignee of the entire right, title, and interest; or2. ☒ an assignee of less than the entire right, title and interest.The extent (by percentage) of its ownership interest is 50 % in the patent application/patent identified above by virtue of either;A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:1. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.2. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.☐ Additional documents in the chain of title are listed on a supplemental sheet.☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

  
Signature09 MAY 2005

Date

Marcus Jonathan William DALTON

Printed or Typed Name

+44 20 8047 4401

Telephone Number

Attorney and Authorised Official

Title

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

<b>POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM</b>	<b>Application Number</b>	PCT/EP2003/008569
	<b>Filing Date</b>	31 July 2003
	<b>First Named Inventor</b>	Ralph BIEMANS
	<b>Title</b>	VACCINE COMPOSITION COMPRISING LIPOOLIGOSACCHARIDE WITH REDUCED PHASE VARIABILITY
	<b>Art Unit</b>	
	<b>Examiner Name</b>	
	<b>Attorney Docket Number</b>	B45309
I hereby appoint: <input checked="" type="checkbox"/> Practitioners associated with the Customer Numbers.      20462 Or <input type="checkbox"/> Practitioner(s) named below:		
Name		Registration Number
As my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.		
Please recognize or change the correspondence address for the above-identified application to: <input type="checkbox"/> The address associated with the above-mentioned Customer Number: Or <input checked="" type="checkbox"/> The address associated with Customer Number 20462 Or <input type="checkbox"/> Firm or Individual Name:		
Address:		
Address:		
City:	State:	Zip:
Country:		
Telephone:	Fax:	
I am the: <input type="checkbox"/> Applicant/Inventor: <input checked="" type="checkbox"/> Assignee or record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)		
<b>SIGNATURE of Applicant or Assignee of Record</b>		
Signature: 	Date: 13 May 2005	
Name: MICHAEL PAUL JENNINGS	Telephone: 617 33654879	
Title and Company: The University of Queensland		
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.		
<input type="checkbox"/> *Total of:      forms are submitted.		

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**STATEMENT UNDER 37 CFR 3.73(b)**

Applicant/Patent Owner: The University of Queensland

International Application No./Patent No.: PCT/EP2003/008569 Filed/Issue Date: 31 July 2003Entitled: **VACCINE COMPOSITION COMPRISING LIPOOLIGOSACCHARIDE WITH REDUCED PHASE VARIABILITY**

The University of Queensland, a corporation, states that it is:

1. ☐ the assignee of the entire right, title, and interest; or2. ☒ an assignee of less than the entire right, title and interest.The extent (by percentage) of its ownership interest is 50 % in the patent application/patent identified above by virtue of either;A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:1. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.2. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.☐ Additional documents in the chain of title are listed on a supplemental sheet.☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.



Signature

13 MAY 2005.

Date

MICHAEL P JENNINGS.

Printed or Typed Name

617 38654879

Telephone Number

PROFESSOR

Title

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Docket No.: B45309

ASSIGNMENT

WHEREAS I/We, Ralph BIEMANS of Rixensart, Belgium, Philippe DENOEL of Rixensart, Belgium, Christiane FERON of Rixensart, Belgium, Carine GORAJ of Rixensart, Belgium, Jan POOLMAN of Rixensart, Belgium and Vincent WEYNANTS of Rixensart, Belgium have made an invention entitled:


VACCINE COMPOSITION COMPRISING LIPOOLIGOSACCHARIDE WITH REDUCED PHASE  
VARIABILITY

for which on April 25, 26, 28 & May 13, 2005 I/we executed an application for Letters  
Patent of the United States of America;


NOW, THEREFORE, in return for valuable consideration paid to me/us by GlaxoSmithKline Biologicals s.a. of Rue de l'Institut 89, B-1330 Rixensart, Belgium (hereinafter "ASSIGNEE"), the receipt of which is hereby acknowledged and intending to be legally bound, I/we do hereby assign unto the said ASSIGNEE, its successors and assigns, the entire right, title and interest in and to the said invention, said executed application, any division, continuation and continuation-in-part of said application and reissue applications, and all Letters Patents of the United States of America to be obtained therefor;

I/we hereby covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment and sale;

In addition I/we agree to provide ASSIGNEE upon its request with all pertinent facts and documents relating to said invention, and said Letters Patent as may be known and accessible to me/us, and to testify as to the same in any interference or litigation related thereto, and to execute further instruments (including divisional, continuation, continuation-in-part or reissue applications, affidavits or other instruments) required to apply for, obtain, maintain and enforce said application and said Letters Patent which may be necessary; this agreement to be binding upon my/our heirs, executors and administrators.

  
\_\_\_\_\_  
Inventor 1  
Ralph BIEMANS

Date: 26/04/2005

  
\_\_\_\_\_  
Inventor 2  
Philippe DENOEL


Date: 25/04/2005

  
\_\_\_\_\_  
Inventor 3  
Christiane FERON

Date: 28/04/2005

  
\_\_\_\_\_  
Inventor 4  
Carine GORAJ

Date: 25/04/2005

  
\_\_\_\_\_  
Inventor 5  
Jan POOLMAN

Date: 25/04/2005

  
\_\_\_\_\_  
Inventor 6  
Vincent WEYNANTS

Date: 25/04/2005

Docket No.: B45309

ASSIGNMENT

WHEREAS I/We, Michael Paul JENNINGS of Brisbane, Queensland, Australia have made an invention entitled:

VACCINE COMPOSITION COMPRISING LIPOOLIGOSACCHARIDE WITH REDUCED PHASE  
VARIABILITY

for which on April 25, 26, 28 & May 13, 2005 I/we executed an application for Letters  
Patent of the United States of America;

NOW, THEREFORE, in return for valuable consideration paid to me/us by The University of  
Queensland of Brisbane, Queensland QLD 4072 Australia (hereinafter "ASSIGNEE"), the receipt of  
which is hereby acknowledged and intending to be legally bound, I/we do hereby assign unto the said  
ASSIGNEE, its successors and assigns, the entire right, title and interest in and to the said invention,  
said executed application, any division, continuation and continuation-in-part of said application and  
reissue applications, and all Letters Patents of the United States of America to be obtained therefor;

I/we hereby covenant that no assignment, sale, agreement or encumbrance has been or will be made  
or entered into which would conflict with this assignment and sale;

In addition I/we agree to provide ASSIGNEE upon its request with all pertinent facts and documents  
relating to said invention, and said Letters Patent as may be known and accessible to me/us, and to  
testify as to the same in any interference or litigation related thereto, and to execute further  
instruments (including divisional, continuation, continuation-in-part or reissue applications, affidavits or  
other instruments) required to apply for, obtain, maintain and enforce said application and said Letters  
Patent which may be necessary; this agreement to be binding upon my/our heirs, executors and  
administrators.

  
Inventor 1  
Michael Paul JENNINGS

Date: 13 MAY 2005